Skip to main content
. 2018 Jul 2;8:9930. doi: 10.1038/s41598-018-27842-y

Figure 4.

Figure 4

Lack of DAPK1 activity impairs Aβ25–35-induced IL-1β maturation and caspase-1 activation in LPS-primed Bv2 cells. (A) LPS-primed cells were treated with DAPK1 inhibitor at different doses (2.5, 5, 10 μM) for 1 h before Aβ25–35 (25 μM) exposure. Amounts of IL-1β in the culture supernatant after 24 h of Aβ25–35 treatment were assessed by ELISA. (B–D) The effects of DAPK1 inhibitor (10 μM) treatment on LPS-induced TNF-α and IL-6 secretion, as well as LPS + Aβ25–35-induced LDH release were determined. (E–J) The effects of DAPK1 inhibitor (10 μM) treatment on the expression of p-MLC, caspase-1, NLRP3, pro-IL-1β and ASC in LPS-primed cells were determined by western blotting analysis (see original blots in Supplementary Fig. S4). Data are expressed as mean ± SEM for at least three independent experiments. ***P < 0.001; #P < 0.05, ###P < 0.001. DI: DAPK1 inhibitor.